Author

Antonio Gasbarrini

HUMAN EXTRACHROMOSOMAL CIRCULAR DNA IS AN EMERGING BIOMARKER IN INFLAMMATORY BOWEL DISEASE
HUMAN EXTRACHROMOSOMAL CIRCULAR DNA IS AN EMERGING BIOMARKER IN INFLAMMATORY BOWEL DISEASE

Antonio Gasbarrini  et al.

PREVALENCE OF, AND MICROBIAL RISK FACTORS FOR, IRRITABLE BOWEL SYNDROME AND FUNCTIONAL DYSPEPSIA AFTER ACUTE GASTROINTESTINAL INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
PREVALENCE OF, AND MICROBIAL RISK FACTORS FOR, IRRITABLE BOWEL SYNDROME AND FUNCTIONAL DYSPEPSIA AFTER ACUTE GASTROINTESTINAL INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS

Antonio Gasbarrini  et al.

EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 6,000 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 6,000 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Antonio Gasbarrini  et al.

ENDOSCOPIC BALLOON DILATATION ASSOCIATED WITH BIOLOGICAL THERAPY IN CROHN’S DISEASE STRICTURES: A SINGLE CENTER EXPERIENCE
ENDOSCOPIC BALLOON DILATATION ASSOCIATED WITH BIOLOGICAL THERAPY IN CROHN’S DISEASE STRICTURES: A SINGLE CENTER EXPERIENCE

Antonio Gasbarrini  et al.

DYNAMICS OF LIVER STIFFNESS PREDICTS HEPATOCELLULAR CARCINOMA AND ASCITES IN PATIENTS WITH HEPATITIS C VIRUS RELATED CIRRHOSIS TREATED WITH DIRECT ACTING ANTIVIRALS
DYNAMICS OF LIVER STIFFNESS PREDICTS HEPATOCELLULAR CARCINOMA AND ASCITES IN PATIENTS WITH HEPATITIS C VIRUS RELATED CIRRHOSIS TREATED WITH DIRECT ACTING ANTIVIRALS

Antonio Gasbarrini  et al.

SPECIFIC GUT MICROBIOTA SIGNATURES ARE ASSOCIATED WITH SYMPTOMATIC LACTOSE MALABSORPTION
SPECIFIC GUT MICROBIOTA SIGNATURES ARE ASSOCIATED WITH SYMPTOMATIC LACTOSE MALABSORPTION

Antonio Gasbarrini  et al.

DYNAMIC CONTRAST-ENHANCED ULTRASOUND (D-CEUS) TO PREDICT BIOLOGICAL BEHAVIOR IN PANCREATIC CANCER: MONOCENTRIC STUDY PRELIMINARY RESULTS
DYNAMIC CONTRAST-ENHANCED ULTRASOUND (D-CEUS) TO PREDICT BIOLOGICAL BEHAVIOR IN PANCREATIC CANCER: MONOCENTRIC STUDY PRELIMINARY RESULTS

Antonio Gasbarrini  et al.

VALIDATION OF CACLD RISK MODEL FOR DIAGNOSIS OF COMPENSATED ADVANCED CHRONIC LIVER DISEASE (CACLD) IN NAFLD PATIENTS
VALIDATION OF CACLD RISK MODEL FOR DIAGNOSIS OF COMPENSATED ADVANCED CHRONIC LIVER DISEASE (CACLD) IN NAFLD PATIENTS

Antonio Gasbarrini  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION
EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION

Antonio Gasbarrini  et al.

RADIOMICS COULD PREDICT SURGERY AT 10 YEARS IN CROHN’S DISEASE
RADIOMICS COULD PREDICT SURGERY AT 10 YEARS IN CROHN’S DISEASE

Antonio Gasbarrini  et al.

TARGETING THE INTESTINAL ECOSYSTEM THROUGH A GUT MICROBIOME TESTING TO TREAT RECURRENT URINARY-TRACT INFECTIONS FROM GUT PATHOBIONTS: A PILOT STUDY
TARGETING THE INTESTINAL ECOSYSTEM THROUGH A GUT MICROBIOME TESTING TO TREAT RECURRENT URINARY-TRACT INFECTIONS FROM GUT PATHOBIONTS: A PILOT STUDY

Antonio Gasbarrini  et al.

MULTIDISCIPLINARY APPROACH IN EOSINOPHILIC OESOPHAGITIS CARE: HOW TO IMPROVE DIAGNOSIS AND MANAGEMENT
MULTIDISCIPLINARY APPROACH IN EOSINOPHILIC OESOPHAGITIS CARE: HOW TO IMPROVE DIAGNOSIS AND MANAGEMENT

Antonio Gasbarrini  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION: A SINGLE CENTRE REAL WORLD EXPERIENCE
EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION: A SINGLE CENTRE REAL WORLD EXPERIENCE

Antonio Gasbarrini  et al.

A MICROBIOME TESTING-BASED PRECISION MEDICINE APPROACH TO TREAT POST-INFECTIOUS IRRITABLE BOWEL SYNDROME: A PILOT STUDY
A MICROBIOME TESTING-BASED PRECISION MEDICINE APPROACH TO TREAT POST-INFECTIOUS IRRITABLE BOWEL SYNDROME: A PILOT STUDY

Antonio Gasbarrini  et al.

SERIAL FECAL MICROBIOTA INFUSIONS BY COLONOSCOPY FOR ACTIVE ULCERATIVE COLITIS: A FEASIBILITY, SAFETY AND TRANSLATIONAL MONOCENTRIC ITALIAN STUDY
SERIAL FECAL MICROBIOTA INFUSIONS BY COLONOSCOPY FOR ACTIVE ULCERATIVE COLITIS: A FEASIBILITY, SAFETY AND TRANSLATIONAL MONOCENTRIC ITALIAN STUDY

Antonio Gasbarrini  et al.

SCREENING OF DONOR FECES WITH A DIRECT STOOL TESTING-BASED APPROACH: FRAMEWORK AND OUTCOMES OF A LARGE-VOLUME DONOR STOOL BIOBANK FOR FECAL MICROBIOTA TRANSPLANTATION
SCREENING OF DONOR FECES WITH A DIRECT STOOL TESTING-BASED APPROACH: FRAMEWORK AND OUTCOMES OF A LARGE-VOLUME DONOR STOOL BIOBANK FOR FECAL MICROBIOTA TRANSPLANTATION

Antonio Gasbarrini  et al.

EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN 426 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN 426 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Antonio Gasbarrini  et al.

EFFECTIVENESS OF HELICOBACTER PYLORI TREATMENTS ACCORDING TO ANTIBIOTIC RESISTANCE: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS OF HELICOBACTER PYLORI TREATMENTS ACCORDING TO ANTIBIOTIC RESISTANCE: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Antonio Gasbarrini  et al.

REAL-LIFE VS TRIAL ACCESS TO BIOLOGICAL THERAPY DIFFERENCES: A 2019-2020 EXPERIENCE IN AN ITALIAN TERTIARY IBD CENTER
REAL-LIFE VS TRIAL ACCESS TO BIOLOGICAL THERAPY DIFFERENCES: A 2019-2020 EXPERIENCE IN AN ITALIAN TERTIARY IBD CENTER

Antonio Gasbarrini  et al.

EFFICACY AND SAFETY OF FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF SEVERE AND SEVERE-COMPLICATED CLOSTRIDIOIDES DIFFICILE INFECTION: REPORT FROM A LARGE-VOLUME FMT CENTER
EFFICACY AND SAFETY OF FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF SEVERE AND SEVERE-COMPLICATED CLOSTRIDIOIDES DIFFICILE INFECTION: REPORT FROM A LARGE-VOLUME FMT CENTER

Antonio Gasbarrini  et al.

Item 21 - 40 / 59
1
2
3